Faes Farma, S.A.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Faes Farma, S.A.
Click Therapeutics And Indivior Collaborate On Prescription Digital Therapeutics In Substance Use Disorder
Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.
News We’re Watching: Boston Scientific's POLARx Is Approved, IABP Recalls, Intricon Opens Facility in Costa Rica
This week, FDA cleared Terumo's Reveos automated whole blood processing system, Abbott adds the Alinity-h hematology system to its comprehensive lab diagnostics lineup, Movano moves forward with "smart ring" technology, and more.
In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill
Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug for the firm – but upcoming Phase II data will need to be compelling.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb and Hannah Daniel discuss highlights from their DTA Summit coverage in Washington. Reed Miller talked to Frank Chan, the president of Medtronic’s Patient Monitoring, about plans for their patient monitoring as an independent company and Bayer AG’s new business unit focusing on digital health.
- Generic Drugs
- OTC, Consumer
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.